Overcoming challenges in cell line engineering
Genome editing enables researchers to build customized cellular models for nearly any gene target, but not without challenges. Merck KGaA, Darmstadt, Germany has developed methods to overcome these challenges and enhance cell line engineering capabilities.

What will you learn?
- Newest strategies for clone screening and genotyping
- Improved workflow for cell line characterization
- Methods to overcome poor transfection efficiency
- Strategies for recalcitrant cell lines
Who may this interest?
- Researchers/scientists; Target discovery, target validation, early oncology discovery, immuno-oncology, immunotherapy, T-cell biology
Speaker
Mark Gerber
Principal R&D Scientist, Supervisor, Cell Design Studio
MilliporeSigma*
Mark obtained his Ph.D. in Biochemistry and Molecular Biology from Saint Louis University School of Medicine, where he used RNAi in Drosophila models to elucidate developmental and biochemical roles for RNA polymerase II-associated transcription factors. Following graduate school, he was a Postdoctoral Fellow at Washington University in St. Louis, where he investigated signaling pathways involved in the development of human meningioma. Mark joined MilliporeSigma* in 2006, and he has worked in the areas of biotherapeutic production, stem cell applications, and gene regulation. He currently supervises the Cell Design Studio team, which performs custom cell line engineering for research and pharma markets using ZFN and CRISPR technologies.
* The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
For a full list of webinars available on RegMedNet click here.
No comments yet.